Midregional proadrenomedullin safely reduces hospitalization in a low severity cohort with infections in the ED: a randomized controlled multi-centre interventional pilot study

What Was Tested

This randomized controlled trial paper looks at Adrenomedullin.

The midregional fragment of proadrenomedullin (MR-proADM) is known to provide accurate short-, mid- and long term prognostic information in the triage and multi-dimensional risk assessment of patients in the emergency department (ED).

In two independent observational cohorts MR-proADM values identified low disease severity patients without risk of disease progression in the ED with no 28 days mortality that wouldn´t require hospitalization.

Who Took Part

Control arm patients received Standard Care.

How the Study Was Run

The researchers set it up as a randomized, multicenter and pilot study.

Random assignment meant chance, not the researchers, decided who got Adrenomedullin and who got the comparison, which limits bias.

Running at several centres spread the Adrenomedullin study over different clinics and patient groups.

It is described as a pilot, a small early test of whether a larger Adrenomedullin study would be practical.

A randomized-controlled interventional multicenter study in 4 EDs in Spain.

The study protocol was approved by Ethics Committees.

The hospitalization rate was compared between the study arms.

What Was Measured

The midregional fragment of proadrenomedullin (MR-proADM) is known to provide accurate short-, mid- and long term prognostic information in the triage and multi-dimensional risk assessment of patients in the emergency department (ED).

The subject headings attached to it are Adrenomedullin, Biomarkers, Emergency Service, Hospital, Hospitalization, Pilot Projects, Prognosis and Protein Precursors.

The authors tagged it with the keywords Discharge, Disease Progression, Emergency Department, Infection, MR-proADM and Readmission.

What This Means in Plain Language

The paper is a randomized, multicenter and pilot study of Adrenomedullin.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (European journal of internal medicine), a journal based in Netherlands.

More context: the Adrenomedullin compound page, all human trials.